Table 1. Characteristics of included studies.
| Study, (Author/year) | Country | Tumor type | Tumor stage | Number of Patients | Male/Female | Age, Median (Range) | Follow-up, months (Range) | Survival Data | NOS Score | |
|---|---|---|---|---|---|---|---|---|---|---|
| Wettstein/2015 [23] | Switzerland | Urothelial Bladder Cancer | Nonmuscle Invasive | 174 | 131/43 | 69.5 (32–92) | 110.6 (32.4–226.8) | DFS | 8 | |
| Turcotte/2015 [5] | A | Canada | High-grade serous ovarian cancer | I–IV | 208 | 0/208 | 61 (34–89) | 36 (1–156) | DFS | 7 |
| B | 1581 | 0/1581 | NR | NR | OS | |||||
| Leclerc/2015 [4] | Canada | Prostate cancer | I–IV | 285 | NR | 62 | 108 | DFS | 7 | |
| Yu/2015 [26] | China | Renal cell cancer | I–IV | 189 | 119/70 | 58 (35–87) | 78 (1–118) | OS, DFS | 8 | |
| Zhang/2015 [24] | China | Rectal cancer | I–IV | 90 | 60/30 | 64.4 ± 12.5 | 88.5 (83–98) | OS | 7 | |
| Xiong/2014 [6] | China | Gallbladder cancer | I–III | 67 | 19/48 | 54.5 ± 10.6 | 18 | OS | 7 | |
| Loi/2013 [2] | Australia | Breast cancer | I–IV | 6209 | 0/6209 | NR | NR | OS | 6 | |
| Lu/2013 [25] | China | Gastric cancer | I–IV | 68 | 43/25 | 49.8 (24–59) | 1–81 | OS | 7 | |
| Oh/2012 [22] | Korea | Epithelial ovarian cancer | I–IV | 167 | 0/167 | 50.3 ± 13.5 | 1–120 | OS, DFS | 8 | |
| Zhi/2012 [28] | China | Breast cancer | I–IV | 2898 | 0/2898 | NR | NR | OS | 6 | |
| Supernat/2012 [29] | Poland | Breast cancer | I–III | 136 | 0/136 | 58.4 (27–86) | 21.6 (1.2–42) | OS, DFS | 7 | |
| Wu/2012 [3] | Validation cohort | China | Colorectal cancer | I–IV | 135 | 75/60 | 59.5 ± 14.0 | 74.8 ± 36.2 | OS | 7 |
| Training cohort | China | Colorectal cancer | I–IV | 223 | 120/103 | 57.9 ± 13.8 | 52.0 ± 21.1 | OS | 7 | |
| Cushman/2015 [27] | USA | Colorectal cancer | IV | 103 | 57/46 | 61.1 (22–83.3) | 69.2 | OS, DFS | 6 | |